Dongsheng Pharmaceutical International Co. Granted Exclusive Sales Rights for Thymosin Alpha 1 InjectionJanuary 4, 2011 10:34 pm | by Bio-Medicine.Org | Comments
NEW YORK, Jan. 5, 2011 /PRNewswire-Asia/ -- Dongsheng Pharmaceutical International Co., Ltd. (the "Company") (OTC Bulletin Board: DNGH ) announced today that it has obtained the exclusive sales rights of Thymosin Alpha 1 Injection in 19 provinces in China from Shanghai Biochemistry...
A recent development â€“ the FDA's intention to rescind a 510(k) medical device registration held by ReGen Biologics Inc. â€“ signals the FDA intends to broaden its regulatory powers, leaving companies in the medical device industry and those that invest in development of medical technologies...
MOUNTAIN VIEW, Calif., Jan. 4, 2011 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that the company will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 8:00 a.m. PT in San Francisco. A live webcast of the presentation will be...
Medical device maker AngioDynamics Inc. said Tuesday its profit edged higher in the fiscal second quarter despite a decline in revenue.AngioDynamics said its profit rose 5 percent to $3.3 million in the quarter ended Nov. 30, up from $3.1 million a year ago. On a per-share basis, its profit was...
Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article(2)January 4, 2011 12:35 pm | by Boston Scientific | Comments
NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was pub
Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA ArticleJanuary 4, 2011 12:34 pm | Comments
NATICK, Mass., Jan. 4, 2011 / PRNewswire / -- Boston Scientific Corporation (NYSE: BSX) today issued the following statement from Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article that was pub
NATICK, Mass., Jan. 4, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of Sadra Medical, Inc. of Los Gatos, California. Â The transaction follows the definitive
(International Association for the Study of Lung Cancer) Online registration opens today for the 14th World Conference on Lung Cancer, the world's largest meeting dedicated to lung and thoracic cancers.
Strategic transaction greatly expands ON Semiconductor?s presence in Japan and is expected to further the company?s growth on a global basis.
A stack of punch cards from a landmark study published in 1966, and the legwork to track down the study's participants years later, has yielded the longest analysis of the effects of lipoproteins on coronary heart disease. The study tracked almost 1,900 people over a 29-year period, which...
Angstron Materials Inc., announced the world?s first commercial graphene application. The ongoing development of touch screens for consumer electronics is driving a growing need for sense data.
Momenta Pharmaceuticals Inc. has appointed Young T. Kwon, former senior director of business development at Biogen Idec, as vice president of business development of the company.
Constellation Pharmaceuticals Inc. has named Eli Lilly and Company veteran James Audia as chief scientific officer of the Cambridge genome-focused drug developer.
Foundation Medicine Inc., a cancer diagnostics startup, has inked a collaboration deal with Swiss drug giant Novartis AG to tailor Foundation's genome-based tests to Novartis' needs.